Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG licensee TolerRx, Inc. raises $35.6m to develop TRX4; Phase III pivotal trial in type 1 diabetes

BTG : 03 November, 2006  (Company News)
BTG plc, the medical innovations company, today announces that TolerRx, Inc. has raised $35.6 million to advance the development of TRX4 as a treatment for type 1 diabetes and plans to commence a Phase III pivotal trial in 2006. TolerRx, BTG's exclusive licensee for the anti-CD3 monoclonal antibody TRX4, is also developing TRX4 as a treatment for psoriasis.
BTG plc, the medical innovations company, today announces that TolerRx, Inc. has raised $35.6 million to advance the development of TRX4 as a treatment for type 1 diabetes and plans to commence a Phase III pivotal trial in 2006. TolerRx, BTG's exclusive licensee for the anti-CD3 monoclonal antibody TRX4, is also developing TRX4 as a treatment for psoriasis.

BTG's pipeline currently comprises 15 assets in clinical development, of which 10 are being developed by licensees.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo